Cargando…
ERAP1 and ERAP2 Enzymes: A Protective Shield for RAS against COVID-19?
Patients with coronavirus disease 2019 (COVID-19) have a wide variety of clinical outcomes ranging from asymptomatic to severe respiratory syndrome that can progress to life-threatening lung lesions. The identification of prognostic factors can help to improve the risk stratification of patients by...
Autores principales: | D’Amico, Silvia, Tempora, Patrizia, Lucarini, Valeria, Melaiu, Ombretta, Gaspari, Stefania, Algeri, Mattia, Fruci, Doriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914632/ https://www.ncbi.nlm.nih.gov/pubmed/33567739 http://dx.doi.org/10.3390/ijms22041705 |
Ejemplares similares
-
Impact of Natural Occurring ERAP1 Single Nucleotide Polymorphisms within miRNA-Binding Sites on HCMV Infection
por: Melaiu, Ombretta, et al.
Publicado: (2020) -
ERAP1 Controls the Interaction of the Inhibitory Receptor KIR3DL1 With HLA-B51:01 by Affecting Natural Killer Cell Function
por: D’Amico, Silvia, et al.
Publicado: (2021) -
Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment
por: Lucarini, Valeria, et al.
Publicado: (2021) -
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
por: D’Amico, Silvia, et al.
Publicado: (2022) -
Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity
por: D’Amico, Silvia, et al.
Publicado: (2023)